Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
1-15 of 4468 results
Atreca raises $35m to advance novel cancer immunotherapies
Atreca, a privately held biotechnology company developing novel therapeutics drawn from human immune responses, has closed its Series B round of financing with an investment totaling $35m.
Drug Research > Drug Discovery & Development > News
GSK to evaluate Insilico’s AI technology to enhance drug discovery process.
By PBR Staff Writer
GlaxoSmithKline and Insilico Medicine are partnering to assess how the latter’s artificial intelligence (AI) technology can help in the drug discovery process.
Drug Research > Drug Discovery & Development > News
Evotec completes Aptuit acquisition
German company Evotec has completed the acquisition of US-based Aptuit.
Drug Research > Drug Discovery & Development > News
Vicarius Pharma secures $21.8m financing
Vicarius Pharma has secured a CHF21m ($21.8m) investment through a Series A preferred stock financing from private investors.
Drug Research > Drug Discovery & Development > News
Oxford BioMedica announces collaboration for gene and cell therapy manufacturing
A new consortium, led by Oxford BioMedica, will take part in a two-year, £2m project focused on gene and cell therapy manufacturing.
Drug Research > Drug Discovery & Development > News
Apellis Pharmaceuticals raises $60m in new funding round
Apellis Pharmaceuticals has completed a $60m Series E preferred stock financing led by Sectoral Asset Management.
Drug Research > Drug Discovery & Development > News
Oxford BioMedica secures commercial supply licence from UK MHRA
Oxford BioMedica has been granted a Manufacturer/Importer License (MIA) from the UK Medicines and Healthcare products Regulatory Agency (MHRA), to manufacture and distribute lentiviral vector material for commercial supply.
Drug Research > Drug Discovery & Development > News
Researchers develop new drug that could treat and limit Parkinson’s disease
Binghamton University researchers have developed a new drug that could possibly limit the progression of Parkinson’s disease and also provide better symptom relief.
Drug Research > Drug Discovery & Development > News
Bristol-Myers Squibb to acquire IFM Therapeutics to expand cancer pipeline
By PBR Staff Writer
Bristol-Myers Squibb has agreed to acquire Boston-based IFM Therapeutics for an upfront payment of $300m to strengthen its oncology pipeline.
Drug Research > Drug Discovery & Development > News
Evotec to acquire Aptuit for $300m
German small molecule drugs developer Evotec has agreed to acquire pharmaceutical services company Aptuit for $300m from private equity firm Welsh, Carson, Anderson & Stowe (WCAS).
Drug Research > Drug Discovery & Development > News
Eagle gets complete response letter from FDA on exertional heat stroke drug RYANODEX
Eagle Pharmaceuticals has received a Complete Response Letter from the US Food and Drug Administration (FDA) for its New Drug Application for RYANODEX (dantrolene sodium) for the treatment of exertional heat stroke (EHS), in conjunction with external cooling methods.
Drug Research > Drug Discovery & Development > News
Evotec, Storm Therapeutics to exploit RNA modulating enzymes for epigenetic drug discovery
Evotec and STORM Therapeutics have expanded their integrated drug discovery collaboration to develop new small molecule epigenetic drugs for oncology and other therapeutic areas.
Drug Research > Drug Discovery & Development > News
GSK to stop 30 drug developments to focus on core therapies
By PBR Staff Writer
GlaxoSmithKline (GSK) has announced its decision to terminate over 30 drug development programs, which it thinks are unlikely to deliver sufficient revenue in the future.
Drug Research > Drug Discovery & Development > News
VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria
VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).
Drug Research > Drug Discovery & Development > News
VenatoRx Pharmaceuticals raises $42m in new funding round
VenatoRx Pharmaceuticals has raised $42m in a Series B funding round led by Versant Ventures and joined by Abingworth and Foresite Capital.
Drug Research > Drug Discovery & Development > News
1-15 of 4468 results